SE‑Cluster

Search

Search markets, companies, evidence, and pages

Machine Verified Markets
Market strategy briefQ2 2026Next refresh: mid-Nov 2026

Lower Spend Concentration + Slower posture

Healthcare Services & Facilities

Lower Spend Concentration + Slower · $892B disclosed spend · led by Geographic Expansion plays · activity cooling across 391 public buyers.

Attractive buyers combine visible acquisition cadence with clear service-line expansion and target sizes that fit their balance sheet.

Geographic Expansion dominantSpend HHI 478Cooling -17

Disclosed acquisition spend is below the atlas median HHI (576), while recent activity is flat or cooling.

Public buyers

391

131 core (10+)

Recorded buys

3,333

700 last 3 yrs

Disclosed spend

$892B

$195B recent

Matched issuers

957

4 segments

Strategy fingerprint

How this market gets bought

Spend-weighted strategy mix from public buyers' 10-K language. Each archetype shows the buyers who lead it.

Geo 24%
Platform 23%
Horiz 17%
Bolt 17%
Tech 13%
Tuck InBolt OnPlatformGeographic ExpansionHorizontal ConsolidationVertical IntegrationTechnology AcquisitionTalent Acquisition

Tuck In

5% mix

Small additive deals folded directly into the existing business.

“The preliminary estimated fair value assigned to goodwill is primarily attributable to synergies expected to arise as a result of the NSH Merger by enhancing the growth profile and diversity of the Company across the healthcare continuum.”

Surgery Partners, Inc. (SGRY) · FY2017

Bolt On

17% mix

Mid-sized acquisitions extending the existing product or service core.

“reflecting management’s commitment to create life-enhancing innovations and to create value through partnerships”

Johnson & Johnson (JNJ) · FY2019

Platform

23% mix

Foundational deals establishing a new platform or business line.

“we acquired worldwide rights to Otezla®, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis”

Amgen Inc. (AMGN) · FY2019

Geographic Expansion

24% mix

Buying density or new geographies to extend the footprint.

“Our businesses face significant competition in all of the markets in which we operate.”

UnitedHealth Group Incorporated (UNH) · FY2025

Horizontal Consolidation

17% mix

Acquiring direct competitors to consolidate the market.

“This acquisition aligns with our strategic plan to grow the Health Benefits segment”

Elevance Health, Inc. (ELV) · FY2024

Vertical Integration

0% mix

Adding upstream or downstream capability inside the value chain.

Technology Acquisition

13% mix

Buying products, IP, or engineering depth for capability gain.

“In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures that when completed we expect may yield approximately $1.0 billion in expense savings. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.”

Biogen Inc. (BIIB) · FY2022

Talent Acquisition

1% mix

Acquisitions led by team or human-capital rationale.

Buyer landscape

Disclosed buyer scale by annual spend

Each bubble is a top public buyer with disclosed acquisition spend. X = average disclosed spend per active year. Y = total disclosed spend. Midlines are buyer medians. Color = dominant strategy archetype.

Below-median disclosed spend per active year, above-median total disclosed spend.Lower Annual Spend / Higher Total SpendAbove-median disclosed spend per active year, above-median total disclosed spend.Higher Annual Spend / Higher Total SpendBelow-median disclosed spend per active year, below-median total disclosed spend.Lower Annual Spend / Lower Total SpendAbove-median disclosed spend per active year, below-median total disclosed spend.Higher Annual Spend / Lower Total Spend$100M$1B$10B$10B$100Bmedian annual $878Mmedian total $10.8BAvg disclosed acquisition spend per active year (log) →Total disclosed spend (log)UNHUnitedHealth Group Incorporated (UNH) Geographic Expansion $114B total · $5.7B / active year 20 active years · 8 buys reportedABBVAbbVie Inc. (ABBV) Platform $72.7B total · $7.3B / active year 10 active years · 6 buys reportedPFEPfizer Inc. (PFE) Platform $63.6B total · $10.6B / active year 6 active years · 19 buys reportedAMGNAmgen Inc. (AMGN) Platform $63.2B total · $4.2B / active year 15 active years · 19 buys reportedNVSNovartis AG (NVS) Geographic Expansion $54.4B total · $6.8B / active year 8 active years · 38 buys reportedGILDGilead Sciences, Inc. (GILD) Technology Acquisition $47.4B total · $3.4B / active year 14 active years · 20 buys reportedAZNAstrazeneca PLC (AZN) Mixed strategy $41.1B total · $10.3B / active year 4 active years · 2 buys reportedBHCBausch Health Companies Inc. (BHC) Bolt On $25.3B total · $1.9B / active year 13 active years · 26 buys reportedJNJJohnson & Johnson (JNJ) Bolt On $23.2B total · $3.9B / active year 6 active years · 13 buys reportedSNYSanofi (SNY) Platform $22.7B total · $3.2B / active year 7 active years · 34 buys reportedELVElevance Health, Inc. (ELV) Horizontal Consolidation $22.7B total · $1.4B / active year 16 active years · 21 buys reportedCVSCVS Health Corporation (CVS) Platform $17.9B total · $3B / active year 6 active years · 7 buys reportedPRGOPerrigo Company plc (PRGO) Geographic Expansion $14.6B total · $2.4B / active year 6 active years · 15 buys reportedRPRXRoyalty Pharma plc (RPRX) Platform $12.4B total · $2.1B / active year 6 active yearsLLYELI LILLY & Co (LLY) Bolt On $12.3B total · $685M / active year 18 active years · 15 buys reportedHCAHCA Healthcare, Inc. (HCA) Mixed strategy $11.7B total · $617M / active year 19 active years · 41 buys reportedCNCCentene Corporation (CNC) Geographic Expansion $11.5B total · $888M / active year 13 active years · 26 buys reportedPAHCPhibro Animal Health Corporation (PAHC) Horizontal Consolidation $10.9B total · $1.2B / active year 9 active years · 6 buys reportedJAZZJazz Pharmaceuticals plc (JAZZ) Platform $10.7B total · $2.1B / active year 5 active years · 7 buys reportedBIIBBiogen Inc. (BIIB) Technology Acquisition $9.6B total · $868M / active year 11 active years · 12 buys reportedHUMHumana Inc. (HUM) Geographic Expansion $9.4B total · $628M / active year 15 active years · 18 buys reportedTHCTenet Healthcare Corp. (THC) Geographic Expansion $7.3B total · $407M / active year 18 active years · 484 buys reportedDGXQuest Diagnostics Inc. (DGX) Geographic Expansion $7.3B total · $457M / active year 16 active years · 41 buys reportedCOSMCosmos Health Inc. (COSM) Geographic Expansion $5.2B total · $2.6B / active year 2 active years · 6 buys reportedMRKMerck & Co., Inc. (MRK) Geographic Expansion $5.1B total · $422M / active year 12 active years · 18 buys reportedUHSUniversal Health Services, Inc. (UHS) Geographic Expansion $4.7B total · $236M / active year 20 active years · 61 buys reportedMDPediatrix Medical Group, Inc. (MD) Geographic Expansion $4.6B total · $242M / active year 19 active years · 160 buys reportedBMYBristol-Myers Squibb Company (BMY) Bolt On $4.5B total · $279M / active year 16 active years · 20 buys reportedASTHAstrana Health, Inc. (ASTH) Geographic Expansion $4.4B total · $402M / active year 11 active years · 21 buys reportedRVMDRevolution Medicines, Inc. (RVMD) Mixed strategy $3.4B total · $840M / active year 4 active years · 2 buys reportedPRPHProphase Labs, Inc. (PRPH) Platform $2.9B total · $584M / active year 5 active years · 1 buys reportedCIThe Cigna Group (CI) Technology Acquisition $2.7B total · $452M / active year 6 active years · 2 buys reportedSEMSelect Medical Holdings Corp. (SEM) Horizontal Consolidation $2.4B total · $142M / active year 17 active years · 5 buys reportedMOHMolina Healthcare, Inc. (MOH) Geographic Expansion $2.2B total · $144M / active year 15 active years · 20 buys reportedENSGEnsign Group, Inc. (ENSG) Horizontal Consolidation $1.9B total · $129M / active year 15 active years · 313 buys reportedSGRYSurgery Partners, Inc. (SGRY) Tuck In $1.5B total · $140M / active year 11 active years · 108 buys reported
BuyerDominant playDisclosed spendSpend / yrBuys3-yr spend trend
UnitedHealth Group IncorporatedUNHGeographic Expansion
$114B
$5.7B8

Steady

-16%

AbbVie Inc.ABBVPlatform
$72.7B
$7.3B6

Cooling

-54%

Pfizer Inc.PFEPlatform
$63.6B
$10.6B19

Accelerating

+246%

Amgen Inc.AMGNPlatform
$63.2B
$4.2B19

Accelerating

+446%

Novartis AGNVSGeographic Expansion
$54.4B
$6.8B38

Accelerating

+243%

Gilead Sciences, Inc.GILDTechnology Acquisition
$47.4B
$3.4B20

Cooling

-85%

Astrazeneca PLCAZNN/A
$41.1B
$10.3B2

Winding down

$41.1B → $19M

Bausch Health Companies Inc.BHCBolt On
$25.3B
$1.9B26

New cycle

$2.2B recent

Johnson & JohnsonJNJBolt On
$23.2B
$3.9B13

Paused

$17.7B prior

SanofiSNYPlatform
$22.7B
$3.2B34

New cycle

$2B recent

Elevance Health, Inc.ELVHorizontal Consolidation
$22.7B
$1.4B21

Steady

+4%

CVS Health CorporationCVSPlatform
$17.9B
$3B7

New cycle

$17.1B recent

Playbook theatre

The language of consolidation, by archetype

Direct sentences from public buyers' 10-K filings, grouped by the strategy they describe.

“Our businesses face significant competition in all of the markets in which we operate.”

UnitedHealth Group IncorporatedUNHFY2025

“we acquired ownership interests in 56 fully operational UCCs and one telehealth center located in Arizona”

Tenet Healthcare Corp.THCFY2023

“We are in a highly competitive industry. Some of our competitors are more established in the health care industry in terms of a larger market share and have greater financial resources than we do in some markets.”

Humana Inc.HUMFY2025

“in 2025, we closed the acquisitions of Anthos Therapeutics, Regulus Therapeutics, and Tourmaline Bio”

Novartis AGNVSFY2025

“We operate in a highly competitive and evolving industry characterized by business consolidations, strategic partnerships, market pressures, and ongoing regulatory and legislative changes at both at the federal and state levels, including healthcare reform initiatives described under the heading "Regulation." Shifts in the political environment may further influence the competitive landscape.”

Centene CorporationCNCFY2025

“The acquisition completed our transformation to a consumer self-care company.”

Perrigo Company plcPRGOFY2023

Submarkets

Where the cadence lives

Activity intensity, lead buyers, and footprint per segment within this market.

Pharma & Biotech Products

1,238

Biotech, specialty pharma, generic drugs, life-science products, and regulated therapeutic platforms.

Buyers

342

Core

102

Spend

$649B

2006–2025 · last year 114

Payer & Provider Services

107

Health plans, provider enablement, care coordination, pharmacy services, and outsourced healthcare operations.

Buyers

11

Core

8

Spend

$181.4B

2006–2025 · last year 8

Care Delivery & Facilities

2,046

Hospitals, senior care, behavioral health, surgery centers, dental, therapy, and site-based care.

Buyers

32

Core

20

Spend

$53.8B

2006–2025 · last year 152

Diagnostics & Lab Services

72

Diagnostics, clinical labs, research services, testing networks, and laboratory workflow platforms.

Buyers

6

Core

1

Spend

$7.8B

2006–2025 · last year 3

Accelerators

Recent 3-yr cadence above prior

8

Coolers

Recent 3-yr cadence below prior

8

Trajectory

20 years of cadence and spend

Annual recorded buys and disclosed spend across the matched buyer set.

01673332006: 95 buys · $62.2B spend · 29 buyers2007: 46 buys · $8.6B spend · 26 buyers2008: 78 buys · $17.1B spend · 30 buyers2009: 64 buys · $16.6B spend · 31 buyers2010: 117 buys · $14.1B spend · 39 buyers2011: 104 buys · $15.7B spend · 37 buyers2012: 146 buys · $23.6B spend · 34 buyers2013: 170 buys · $14.3B spend · 46 buyers2014: 126 buys · $24.4B spend · 55 buyers2015: 191 buys · $71.9B spend · 46 buyers2016: 134 buys · $62.1B spend · 52 buyers2017: 197 buys · $22.6B spend · 45 buyers2018: 231 buys · $35.8B spend · 67 buyers2019: 163 buys · $54.4B spend · 67 buyers2020: 164 buys · $104.5B spend · 68 buyers2021: 333 buys · $82.7B spend · 96 buyers2022: 274 buys · $66.5B spend · 98 buyers2023: 159 buys · $84.6B spend · 78 buyers2024: 289 buys · $69.8B spend · 78 buyers2025: 252 buys · $40.5B spend · 90 buyers2006: 95 buys · $62.2B spend · 29 buyers2007: 46 buys · $8.6B spend · 26 buyers2008: 78 buys · $17.1B spend · 30 buyers2009: 64 buys · $16.6B spend · 31 buyers2010: 117 buys · $14.1B spend · 39 buyers2011: 104 buys · $15.7B spend · 37 buyers2012: 146 buys · $23.6B spend · 34 buyers2013: 170 buys · $14.3B spend · 46 buyers2014: 126 buys · $24.4B spend · 55 buyers2015: 191 buys · $71.9B spend · 46 buyers2016: 134 buys · $62.1B spend · 52 buyers2017: 197 buys · $22.6B spend · 45 buyers2018: 231 buys · $35.8B spend · 67 buyers2019: 163 buys · $54.4B spend · 67 buyers2020: 164 buys · $104.5B spend · 68 buyers2021: 333 buys · $82.7B spend · 96 buyers2022: 274 buys · $66.5B spend · 98 buyers2023: 159 buys · $84.6B spend · 78 buyers2024: 289 buys · $69.8B spend · 78 buyers2025: 252 buys · $40.5B spend · 90 buyers20062011201620212025
Recorded buysDisclosed spend (rescaled)